Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 3550 clinical trials
A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older

The purpose of the study is to evaluate safety and immunogenicity of various respiratory syncytial virus (RSV) pre-Fusion (preF)-based vaccine components followed by expanded safety evaluation and durability/revaccination evaluation of the selected RSV preF-based vaccine formulation in participants aged greater than or equal to (>=) 60 years in stable health.

Accepts healthy volunteers
  • 16 Jun, 2022
  • 9 locations
A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19.

This is a phase III clinical study to assess the safety, tolerability and immunogenicity of PHH-1V as a booster dose in healthy adult subjects vaccinated against COVID-19 with the Comirnaty, Spikevax, Vaxevria or Janssen vaccine.

Accepts healthy volunteers
  • 20 Apr, 2022
  • 16 locations
A Study of Acute Respiratory Infections in Global Outpatient Setting (ARGOS)

participants presenting with acute respiratory infections (ARIs) in outpatient settings during the influenza/RSV season and to evaluate the association between lower respiratory tract disease (LRTD) and ARI

  • 29 May, 2022
  • 11 locations
Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

This trial consists of three parts, Part A, Part B, and Part C, and will evaluate the safety and immunogenicity of a third booster injection of the multivalent vaccine BNT162b2 (B.1.1.7 + B.1.617.2), and the safety and immunogenicity of a third booster injection of the monovalent vaccine BNT162b2 (B.1.617.2) or …

Accepts healthy volunteers
  • 03 Jul, 2022
  • 25 locations
Selective High Frequency Oscillatory Ventilation (HFOV) for Neonates

Neonatal respiratory distress syndrome (RDS) remains a major respiratory disorder for the increasing preterm population, and its incidence has been confirmed to be increased gradually with

acute respiratory distress
high frequency oscillatory ventilation
assisted breathing
pulmonary surfactant
  • 24 Feb, 2021
  • 1 location
Minor Stroke Therapy Evaluation (MOSTE)

Stroke represents the fourth leading cause of death in industrialized nations, after heart disease, cancer, and chronic lower respiratory disease. Approximately one-quarter of the patients

diffusion weighted imaging
heart disease
ischemic stroke
  • 12 May, 2022
  • 1 location
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)

This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, improves outcomes when compared to a platinum chemotherapy-based regimen chosen by the Investigator from a list of standard of care treatments, as measured primarily by progression free survival (PFS), for …

measurable disease
treatment regimen
stage iv non-small cell lung cancer
progressive disease
  • 26 May, 2022
  • 80 locations
Smoking Cessation Programme in Workplaces in Hong Kong (Phase )

Smoking causes cardiovascular and respiratory diseases, cancers and diabetes, and it has been a leading risk factor for death globally. Despite the availability of smoking cessation services

  • 01 May, 2021
  • 1 location
Comparison of Procedural Yield of Bronchoalveolar Lavage Using Three Different Techniques in Subjects Undergoing Flexible Bronchoscopy (BAL-3T)

compare the three methods of obtaining BAL in subjects undergoing BAL for various respiratory diseases

  • 30 Jun, 2022
  • 2 locations
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-945, a selective EGFR inhibitor, as monotherapy or in combination with osimertinib.

egfr t790m
  • 19 Apr, 2022
  • 16 locations